Silico Research has recently completed an analysis of comments from respondents about the role of leadership in alliances and business development relationships. Turns out that sometimes leadership is an enabler and sometimes its a hindrance. Click the link below to see a selection of comments about the role of leadership in the success or failure of alliances.
We have undetaken an analysis of what goes wrong in decision-making in alliances and business development relationships. Check to see if the complaints from some of the partners we have surveyed sound familiar.
Silico Research is a research consultancy that has been a trusted adviser and provider of research services for more than ten years to global companies on strategic alliances, partnering, relationships and reputation management both within the organisation and externally. Our current and past clients include AstraZeneca, Eli Lilly, IBM, Merck & Co, Merck Serono, Novartis and Roche. These and other clients come to Silico Research when they need confidential high-quality advice about their strategic alliances and feedback from partners, often involving deals worth billions of dollars.
Silico Research has announced the launch of the Business Development Programme designed to be used by organisations to assess and benchmark their business development performance by polling senior executives in organisations that they have reached out to as part of their business development operations.
Clients come to us, for example, when they need to understand how they are perceived by their community and large, when they are about to forge a partner acquisition strategy, when they need to calibrate a partner communication strategy or when they want to improve management of a portfolio of existing alliances. What sets Silico Research apart is the evidence-based, empirical, nature of our analysis. Our independent, honest, fact-driven advice enables clients to make distinctive, lasting and substantial improvements in their strategic alliance and partnering capabilities.
Silico has recently announced the launch of the latest version of the BioPartnering Programme. Expanded and extensively redesigned, BioPartnering that consists of a cluster of services that, together, provide the most comprehensive source of insight into the current state of strategic alliances and collaborations in the biopharmaceutical sector available today. BioPartnering currently includes three core services: the BioPartnering Programme, the BioPartnering Current Partners Programme and the BioPartnering Business Development Programme.
The results of the previous surveys including rankings of the top companies in each survey are still available.
Silico has released the latest version of its benchmarking database for teams in strategic alliance management and business development. The benchmarking database now includes over 80,000 strategic alliance, partnering and collaboration-related ratings, comments and keywords.
Silico Research has released a white paper examining the relationship between trust and the success of a strategic alliance or collaboration based on our large database of data about strategic alliances. The results of our analysis contradict 'conventional wisdom'.
The CRO Insights+ Tracker Programme gathers feedback from researchers and investigators in the life sciences to assess the reputation of the largest providers of outsourced research and development services in the sector. The Programme tracks feedback about the organisations across a range of factors including responsiveness, openness and willingness to share information, commitment to trust, reliability and an ethical approach to research and ability to attract, develop and keep talented people.
Using our benchmarking database of feedback in hundreds of strategic alliance and similar surveys we have examined the claims made by academics and industry observers about the failure rate for strategic alliances and found them, well....pretty far off the mark.
The Current Partners/Voice of the Partner Programme is a comprehensive assessment of the strengths and weaknesses of a life science organisation as a partner. The Programme covers more than seventy measures, ranging from cultural factors through to the governance of the strategic alliance. The Programme has been developed over ten years of working closely with many of the top strategic alliance management teams in the sector.
Recent analysis by Silico Research has found that senior life science executives in companies based in the Asia-Pacific region are more positive about the prospects for strategic alliances with large pharmaceutical and biotechnology companies. Of the top six countries in terms of attitude to strategic alliances five were from the Asia-Pacific region. Of the bottom six counties in terms of attitude to strategic alliances not a single one was from that region.
Silico has recently announced the launch of the Partnering Benchmarks Programme. The purpose of the Programme is to generate and share information about the use of benchmarking data by strategic alliance and collaboration management teams in a number of sectors including the biopharmaceutical sector. The data provided by respondents will be aggregated and anonymized before being shared with participating organisations.
The Strategic Alliance Success Factors Programme is designed to share information about the most important factors that affect the success or failure of partnerships, strategic alliances, collaborations, channel, outsourcing and other external relationships across all sectors. Participants in the Programme are asked to describe factors that have affected the success or failure of a strategic alliance, the importance of the factor and the responsibility of each party for that factor.
Silico Research's Strategic Alliance Healthcheck Tracker is used by organisations that want to get a complete 360 assessment of the health of a strategic alliance by gathering data from the team members on both sides of the strategic alliance. The survey is administered by Silico Research as an independent intermediary on behalf of the partners.